News

The proceeds are to be primarily used for advancing its clinical trials in the US and Canada evaluating the safety and efficacy of its bioenergetic altered energy metabolism-directed

B T Zhu, professor of pharmacology, toxicology and therapeutics at the University of Kansas, has demonstrated that estriol has strong immunomodulating effects versus other estrogens through its ability

At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications. Additionally they have shown

A total of 21 patients with bronchiectasis were enrolled and randomized into this, double-blind, placebo controlled Phase II study. The purpose of the trial is to investigate safety

The agreement, effective January 1, 2009, has a three-year initial term and includes an option to extend for two additional years. InnerCool’s RapidBlue System is a thermal regulating

Hawaii Biotech has developed a West Nile sub-unit vaccine designed with high fidelity to the native viral antigen in order to provide protective immunity to the recipients. The

Under the agreement, RTI Biologics will process soft tissue allograft and xenograft implants to help patients in ENT applications for distribution by ENTrigue. Long term, the two companies

Most recently, Dr Cagle has served as senior vice president of R&D and chief scientific officer of Alcon Laboratories, a subsidiary of Alcon, Inc, an eye care company.

Schering-Plough has selected Huya to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in